

## A plasma protein marker panel for diagnosis of colorectal cancer (P-1214)

### Key facts

- Plasma protein marker panel for diagnosis and stratification of colorectal cancer
- Core set of 8 protein markers performing with an AUC [95% CI] of 0.76 [0.65–0.85] / specificity of 44% [24–72%] and a sensitivity of 90%.

### Abstract

Sigmoidoscopy and colonoscopy, the current gold standards for detection of CRC in the distal and total colorectum, respectively, are limited by several disadvantages, such as high costs, limited resources and poor compliance. So other cost effective and sensitive methods for the early detection of colorectal cancer are urgently needed and very important from the health economic standpoint. The invention offers a plasma protein biomarker set that can be used as a diagnostic tool for diagnosis and stratification of colorectal cancer.

### The Technology and Development Stage

Based on the prospective BliTz study from 2005–2012 including approximately 5500 participants a panel of 17 plasma proteins was identified by analysis of 35 CRC patients who were compared to a representative sample of 54 controls free of colorectal neoplasms. This set was further reduced to a core panel of 8 proteins without substantial loss of predictive power.

### Applications and Commercial Opportunity

DKFZ is looking for a commercial partner for further development of the marker panel alone or in combination with other markers towards clinical application.

### Inventors

The investigators and inventors are: Chen Hongda and Hermann Brenner, both of DKFZ.

### Scientific Reference

Head-to-Head Comparison and Evaluation of 92 Plasma Protein Biomarkers for Early Detection of Colorectal Cancer in a True Screening Setting. Chen H. et al. [Clin Cancer Res. 2015 Jul 15;21\(14\):3318-26](#)

### Intellectual Property

A priority patent application “Biomarker panel for diagnosing cancer” EP 15161465.8 has been filed at the Europe Patent Office March 27, 2015. The subsequent international patent application was published as [WO2016156128](#).

### Further Information

No further public information is currently available, but further information (speaking with the inventor) is available under a signed Confidential Disclosure Agreement (CDA).

### DKFZ Contact:

For further information, including a CDA, please contact:

Dr. Frieder Kern  
Deutsches Krebsforschungszentrum  
Technology Transfer Office T010  
Email: [F.Kern@dkfz.de](mailto:F.Kern@dkfz.de)  
Tel.: +49-(0)6221-42-2952  
Fax: +49-(0)6221-42-2956